Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

BTG:LN

722.500 GBp 16.500 2.23%

As of 12:35:14 ET on 03/26/2015.

Snapshot for BTG PLC (BTG)

Open: 733.500 Day's Range: 721.500 - 736.500 Volume: 610,546
Previous Close: 739.000 52wk Range: 490.200 - 834.500 1-Yr Rtn: +27.43%

Stock Chart for BTG

No chart data available.
  • BTG:LN 722.500
  • 1D
  • 1M
  • 1Y
739.000
Interactive BTG Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BTG

Current P/E Ratio (ttm) 65.7416
Estimated P/E(03/2015) 43.7879
Relative P/E vs. UKX -
Earnings Per Share (GBP) (ttm) 0.1099
Est. EPS (GBP) (03/2015) 0.1650
Est. PEG Ratio 1.7895
Market Cap (M GBP) 2,758.34
Shares Outstanding (M) 381.78
30 Day Average Volume 606,870
Price/Book (mrq) 4.5116
Price/Sale (ttm) 7.9408
Dividend Indicated Gross Yield -%
Cash Dividend (GBp) -
Dividend Ex-Date 06/07/2000
5 Year Dividend Growth -
Next Earnings Announcement 05/19/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BTG

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for BTG

BTG plc licenses, develops and commercializes pharmaceuticals and has a pipeline of development programs targeting neurological and other disorders, including varicose veins. The Company also has a substantial and growing revenue stream of milestone payments and royalties from out-licensed products.

Pamela Louise MakinCEO/Executive DirectorRolf SoderstromCFO/Executive Director
Peter StratfordCTO:Interventional MedicineGuenter R JanhoferChief Medical Officer/Head:Dev
More Company Profile & Key Executives for BTG

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil